Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OvaRex Consolidation in Ovarian Cancer
NCT00003634Phase 2Unknown
- Sponsor
- AltaRex Medical
- Start
- Apr 1998
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of oregovomab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by AltaRex Medical. Status: unknown.
02
Drugs
oregovomab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00003634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003634.